Long-term Study of Cariprazine in Patients With Schizophrenia

Conditions

• Schizophrenia

Eligibility Criteria

Sex

ALL

Age

18 Years - 60 Years

Healthy Volunteers

Not accepted

Interventions

• Cariprazine — DRUG
  Cariprazine was supplied in capsules.

Study Details

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

Key Dates

Start date

May 31, 2010

Status verified

Jul 2019

Primary completion

Jan 31, 2013

Completion

Jan 31, 2013

Study Design

Enrollment

752 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Cariprazine
  Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.

Primary Outcome Measure

Change From Baseline to Week 48 in the PANSS Total Score [ Time Frame: Baseline to Week 48 ]

Locations (39)

Find similar trials in Little Rock, AR

Related Studies

• Zyprexa® Relprevv™ Patient Care Program
  Enrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
• Database Registry for Neural Network Biomarkers in Psychosis
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
  Recruiting · Yale University · New Haven, Connecticut
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
  PHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania